ABSTRACT
Vaccination certainly is the best way to fight against the COVID-19 pandemic. In this study, the seroconversion effectiveness of two vaccines against severe acute respiratory syndrome coronavirus 2 was assessed in healthcare workers: virus-inactivated CoronaVac (CV, n = 303), and adenovirus-vectored Oxford-AstraZeneca (AZ, n = 447). The immunoglobulin G (IgG) antibodies anti-spike glycoprotein and anti-nucleocapsid protein were assessed by enzyme-linked immunosorbent assay at the time before vaccination (T1), before the second dose (T2), and 30 days after the second dose (T3). Of all individuals vaccinated with AZ, 100% (n = 447) exhibited seroconversion, compared to 91% (n = 276) that were given CV vaccine. Among individuals who did not respond to the CV, only three individuals showed a significant increase in the antibody level 4 months later the booster dose. A lower seroconversion rate was observed in elders immunized with the CV vaccine probably due to the natural immune senescence, or peculiarity of this vaccine. The AZ vaccine induced a higher humoral response; however, more common side effects were also observed. Nonvaccinated convalescent individuals revealed a similar rate of anti-spike IgG to individuals that were given two doses of CV vaccine, which suggests that only a one-shot COVID-19 vaccine could produce an effective immune response in convalescents.
Subject(s)
COVID-19 Vaccines , COVID-19 , Adenoviridae/genetics , Aged , Antibodies, Viral , Brazil , COVID-19/prevention & control , Health Personnel , Humans , Immunoglobulin G , Pandemics/prevention & controlABSTRACT
Vaccination certainly is the best way to fight against the COVID19 pandemic. In this study, the seroconversion effectiveness of two vaccines against severe acute respiratory syndrome coronavirus 2 was assessed in healthcare workers: virusinactivated CoronaVac (CV, n= 303), and adenovirusvectored OxfordAstraZeneca (AZ, n= 447). The immunoglobulin G (IgG) antibodies antispike glycoprotein and antinucleocapsid protein were assessed by enzymelinked immunosorbent assay at the time before vaccination (T1), before the second dose (T2), and 30 days after the second dose (T3). Of all individuals vaccinated with AZ, 100% (n= 447) exhibited seroconversion, compared to 91% (n= 276) that were given CV vaccine. Among individuals who did not respond to the CV, only three individuals showed a significant increase in the antibody level 4 months later the booster dose. A lower seroconversion rate was observed in elders immunized with the CV vaccine probably due to the natural immune senescence, or peculiarity of this vaccine. The AZ vaccine induced a higher humoral response; however, more common side effects were also observed. Nonvaccinated convalescent individuals revealed a similar rate of antispike IgG to individuals that were given two doses of CV vaccine, which suggests that only a oneshot COVID19 vaccine could produce an effective immune response in convalescents.
Subject(s)
Glycoproteins , SARS-CoV-2 , Immunoglobulin G , Nucleocapsid ProteinsABSTRACT
Aim: To explore the association of circulating miRNAs with adiposity, metabolic status and inflammatory biomarkers in patients with metabolic syndrome (MetS). Methods: Serum levels of 372 miRNAs were measured in patients with (n = 6) and without MetS (n = 6) by quantitative PCR array, and dysregulated miRNAs were validated in a larger cohort (MetS, n = 89; non-MetS, n = 144). Results: In the screening study, seven miRNAs were dysregulated in patients with MetS, and miR-421 remained increased in the validation study. miR-421 was associated with a high risk of MetS and insulin resistance and hypertension and correlated with glycated hemoglobin, triacylglycerols, high-sensitivity CRP, IL-6, resistin and adiponectin (p < 0.05). Conclusion: Circulating miR-421 is a potential biomarker for insulin resistance, metabolic dysregulation and inflammatory status in patients with MetS.
Subject(s)
Biomarkers/blood , Gene Expression Regulation , Inflammation/pathology , Insulin Resistance , Metabolic Syndrome/complications , MicroRNAs/genetics , Adult , Aged , Aged, 80 and over , C-Reactive Protein/analysis , Female , Follow-Up Studies , Humans , Inflammation/blood , Inflammation/etiology , Male , MicroRNAs/blood , Middle Aged , Prognosis , Resistin/blood , Triglycerides/bloodABSTRACT
ABSTRACT: To explore the association of circulating miRNAs with adiposity, metabolic status and inflammatory biomarkers in patients with metabolic syndrome (MetS). METHODS: Serum levels of 372 miRNAs were measured in patients with (n = 6) and without MetS (n = 6) by quantitative PCR array, and dysregulated miRNAs were validated in a larger cohort (MetS, n = 89; non-MetS, n = 144). RESULTS: In the screening study, seven miRNAs were dysregulated in patients with MetS, and miR-421 remained increased in the validation study. miR-421 was associated with a high risk of MetS and insulin resistance and hypertension and correlated with glycated hemoglobin, triacylglycerols, high-sensitivity CRP, IL-6, resistin and adiponectin (p < 0.05). CONCLUSION: Circulating miR-421 is a potential biomarker for insulin resistance, metabolic dysregulation and inflammatory status in patients with MetS.
Subject(s)
Metabolic Syndrome , Adiponectin , Adiposity , Insulin Resistance , MicroRNAs , InflammationABSTRACT
BACKGROUND: Studies have pointed out a higher mortality after coronary artery bypass surgery (CABG) in patients with stent. OBJECTIVE: To evaluate inflammatory markers in peripheral blood cells and in coronary artery tissue samples obtained during CABG in patients with stent compared to controls. METHODS: The case series consisted of two groups, one with previous stent implantation (n = 41) and one control (n = 26). The expression of the LIGHT, IL-6, ICAM, VCAM, CD40, NFKB, TNF, IFNG genes was analyzed in peripheral blood cells collected preoperatively. The coronary artery was evaluated for: interleukin-6, ICAM, VCAM, CD40, NFKB, TNF-alpha and IFN-gamma by immunohistochemistry. A total of 176 tissue samples were grouped for analysis in: A1- arteries with stent (n = 38); A2- native arteries from patients with stent in another artery (n = 68); and A3- arteries without stent from controls undergoing routinely CABG surgery (n = 70). A significance level of 0.05 was adopted. RESULTS: Patients with stent showed higher TNF (p = 0.03) and lower CD40 gene expression (p = 0.01) in peripheral blood cells than controls without stent. In coronary artery samples, the TNF-alpha protein staining was higher in the group A1, not only in the intima-media layer (5.16 ± 5.05 vs 1.90 ± 2.27; p = 0.02), but also in the adipose tissue (6.69 ± 3.87 vs 2.27 ± 4.00; p < 0.001). Furthermore, group A1 had a higher interleukin-6 protein staining in adipose tissue than group A3 (p = 0.04). CONCLUSION: We observed a persistently higher systemic TNF expression associated with exacerbated TNF-alpha and interleukin-6 local production in patients with stents. This finding may contribute to a worse clinical outcome.
Subject(s)
Blood Cells , Stents , Percutaneous Coronary Intervention , InflammationABSTRACT
BACKGROUND: Studies have pointed out a higher mortality after coronary artery bypass surgery (CABG) in patients with stent. OBJECTIVE: To evaluate inflammatory markers in peripheral blood cells and in coronary artery tissue samples obtained during CABG in patients with stent compared to controls. METHODS: The case series consisted of two groups, one with previous stent implantation (n = 41) and one control (n = 26). The expression of the LIGHT, IL-6, ICAM, VCAM, CD40, NFKB, TNF, IFNG genes was analyzed in peripheral blood cells collected preoperatively. The coronary artery was evaluated for: interleukin-6, ICAM, VCAM, CD40, NFKB, TNF-alpha and IFN-gamma by immunohistochemistry. A total of 176 tissue samples were grouped for analysis in: A1- arteries with stent (n = 38); A2- native arteries from patients with stent in another artery (n = 68); and A3- arteries without stent from controls undergoing routinely CABG surgery (n = 70). A significance level of 0.05 was adopted. RESULTS: Patients with stent showed higher TNF (p = 0.03) and lower CD40 gene expression (p = 0.01) in peripheral blood cells than controls without stent. In coronary artery samples, the TNF-alpha protein staining was higher in the group A1, not only in the intima-media layer (5.16 ± 5.05 vs 1.90 ± 2.27; p = 0.02), but also in the adipose tissue (6.69 ± 3.87 vs 2.27 ± 4.00; p < 0.001). Furthermore, group A1 had a higher interleukin-6 protein staining in adipose tissue than group A3 (p = 0.04). CONCLUSION: We observed a persistently higher systemic TNF expression associated with exacerbated TNF-alpha and interleukin-6 local production in patients with stents. This finding may contribute to a worse clinical outcome.
Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Arteritis/etiology , Biomarkers/blood , Blood Cells/metabolism , Myocardial Revascularization/adverse effects , Stents/adverse effects , Arteritis/diagnosis , Case-Control Studies , Female , Humans , Immunohistochemistry , Male , Middle Aged , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
O presente trabalho tem como finalidade analisar os princípios da equivalência terapêutica e da conversibilidade de dois preparados farmacêuticos com ciclosporina emulsäo: o produto referência e a ciclosporina microemulsäo genérica. Estudo multicêntrico, randomizado, com 25 transplantados cardíacos com evoluçäo maior de um ano e com terapia imunossupressora estável. O protocolo escolhido foi o X latino. Segundo este protocolo, cada paciente é seu próprio controle, e, durante a execuçäo da pesquisa, realiza-se o cruzamento da medicaçäo testada. Após assinatura de consentimento informado e avaliaçäo clínico-laboratorial inicial, os pacientes säo randomizados para iniciar com ciclosporina padräo ou com ciclosporina genérica. A cada 15 dias, os pacientes realizam novos contrtoles clínico e laboratorial e trocam de medicamentos. No total, säo dois períodos de observaçäo com duas rodadas de troca em cada. Os parâmetros farmacocinéticos dos dois produtos, a ciclosporinemia e a área sob a curva näo mostraram diferenças estatísticamente significativas. O efeito clínico e os efeitos colaterais foram semelhantes no período de observaçäo. Os resultados confirmam a total conversibilidade entre a ciclosporina microemulsäo padräo e a genérica.(au)